Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

What the trial testedrandomised · 1,595 people · 2021

Randomised comparison

4.9×3.6× to 6.6×

Bigger than almost all on the map

As reported

OR 4.88, 95% CI 3.58–6.64

the abstract, start to end

… of 388 vs 107 [28.5%] of 376; odds ratio 4.88, 95% CI 3.58 to 6.64; …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

OR 4.883.58–6.64

GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely

0.900.90 without it

← favours treatmentfavours comparator →

this paperthis papermore certainless certain

1 / 5

2021

…

2025

2026

this paperpooled ittrialcites it